Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

• Published in: Mediators of Inflammation Vol. 2010; no. 2010; pp. 1 - 11
• Main Authors: Ferreira, Liliana, Teixeira-de-Lemos, Edite, Pinto, Filipa, Parada, Belmiro, Mega, Cristina, Vala, Helena, Pinto, Rui, Garrido, Patrícia, Sereno, José, Fernandes, Rosa, Santos, Paulo, Velada, Isabel, Melo, Andreia, Nunes, Sara, Teixeira, Frederico, Reis, Flávio
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Limiteds 01.01.2010; Hindawi Puplishing Corporation; Hindawi Publishing Corporation; Hindawi Limited; Wiley
• Subjects: Animals; Blood Glucose - analysis; Blood Pressure - drug effects; Body Weight - drug effects; C-Reactive Protein - analysis; Complications and side effects; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diabetes Mellitus, Type 2 - pathology; Diabetes therapy; Dipeptidyl-Peptidase IV Inhibitors - pharmacology; Disease Models, Animal; Dosage and administration; Drug therapy; Glycated Hemoglobin - analysis; Inflammation; Insulin - blood; Insulin Resistance; Interleukin-1beta - blood; Lipids - blood; Male; Oxidative stress; Oxidative Stress - drug effects; Pancreas - drug effects; Pancreas - pathology; Pyrazines - pharmacology; Rats; Sitagliptin; Sitagliptin Phosphate; Triazoles - pharmacology; Type 2 diabetes; Portugal
• ISSN: 0962-9351; 1466-1861
• DOI: 10.1155/2010/592760

The purpose of this paper is to evaluate the chronic effect of sitagliptin on metabolic profile, inflammation, and redox status in the Zucker Diabetic Fatty (ZDF) rat, an animal model of obese type 2 diabetes. Diabetic and obese ZDF (fa/fa) rats and their controls (ZDF +/+) were treated during 6 weeks with vehicle (control) and sitagliptin (10 mg/kg/bw). Glucose, HbA1c, insulin, Total-c, TGs, IL-1β, TNF-α, CRPhs, and adiponectin were assessed in serum and MDA and TAS in serum, pancreas, and heart. Pancreatic histology was also evaluated. Sitagliptin in diabetic rats promoted a decrease in glucose, HbA1c, Total-c, and TGs accompanied by a partial prevention of insulinopenia, together, with a decrease in CRPhs and IL-1β. Sitagliptin also showed a positive impact on lipid peroxidation and hypertension prevention. In conclusion, chronic sitagliptin treatment corrected the glycaemic dysmetabolism, hypertriglyceridaemia, inflammation, and hypertension, reduced the severity of the histopathological lesions of pancreatic endocrine and exocrine tissues, together with a favourable redox status, which might be a further advantage in the management of diabetes and its proatherogenic comorbidities.